Background: High household peanut consumption is associated with the develop-
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| INTRODUCTION
Peanut allergy has increased, 1,2 is a leading cause of anaphylaxis in food allergy 3 and has a significant impact on quality of life for the child and their family. 4, 5 Most children react on first known oral exposure to peanut; thus, sensitization must be occurring earlier. 6, 7 Understanding the way children become sensitized to peanut is therefore imperative to prevent this condition. Observational 8 and animal work 9, 10 suggests that epicutaneous peanut exposure and early-onset severe eczema may play an important role in peanut sensitization. Epicutaneous exposure may be the route that peanut levels in dust sensitize a child in early life, particularly if the skin barrier is broken through eczema or specific genetic mutations associated with skin barrier dysfunction (eg filaggrin (FLG) mutations or eczema). We have recently shown in the Manchester Asthma and Allergy Study (MAAS) and Consortium of Food Allergy Research (CoFAR) cohort that FLG loss-of-function mutations and eczema severity, respectively, can increase the impact of early EPE on peanut sensitization and allergy. 11, 12 A dose-response relationship has also been demonstrated between household peanut consumption (used as an indirect marker for environmental peanut exposure: EPE) and the risk of developing peanut allergy in young children. 13 Fox et al compared household peanut consumption in peanut allergic individuals against children who were at high risk of developing peanut allergy (due to the presence of egg allergy) but had not developed peanut allergy. Household peanut consumption was ten times higher in households with infants with peanut allergy vs children with egg allergy without peanut allergy but was only 3 times higher in non-atopic controls, highlighting that household peanut consumption was more likely to be associated with peanut allergy in high-risk children. 13 Household peanut consumption and peanut sensitization have also been associated in other studies. 14 Peanut antigen in the infant's bed dust and play-area-dust is highly positively correlated with household peanut consumption and stimulates basophils from peanut allergic children, thus has the potential to also sensitize individuals. 15 Peanut sensitization (specific IgE ≥ 0.35kU/L) is present in up to 10% of children, and protein allergen molecule analysis of the seed storage proteins in peanut (Ara h 1, 2 and 3) has been shown to improve the specificity and sensitivity of diagnosing peanut allergy. 16, 17 In BAMSE, children with IgE reactivity to Ara h 1, 2 or 3 at age 8 years (but not Ara h 8) reported peanut allergic symptoms in 87% of cases, whereas children with IgE reactivity exclusively to Ara h 8 reported peanut allergic symptoms in only 17% of cases which were also milder. 18 Sweden has high levels of birch pollen sensitization which explains the Bet v 1 in-vitro cross-reactivity with peanut Ara h 8; [18] [19] [20] thus, in this study, we differentiated between primary peanut sensitization (IgE reactivity to Ara h 1, 2 or 3) and pollen cross-reactivity (IgE reactivity to Ara h 8).
This study aimed to assess whether EPE (as defined by peanut protein levels in household dust) is a risk factor for the development of school-age peanut sensitization. The analysis was carried out in two steps for financial and logistical reasons; firstly among high-risk children (with parental atopy matched to peanut sensitized cases), in a nested cases analysis and secondly among the whole studied population (a cohort analysis). Given previous findings, we also wanted to ascertain the modifying effects of FLG loss-of-function mutations, infantile eczema and preceding egg sensitization.
| METHODS
The BAMSE study is an unselected Swedish population birth cohort.
The design and methodology are described elsewhere. 21 In brief, Parental atopy was defined as a doctor's diagnosis of asthma and prescription of asthma medication and/or a doctor's diagnosis of hayfever in combination with furred pets and/or pollen allergy at the time of questionnaire. This definition of parental atopy was selected rather than the same definition with inclusion of a doctor's diagnosis of eczema (excluding contact dermatitis), because the children of parents with atopy including eczema were less atopic (lower infantile eczema), and parental atopy including eczema was not associated with the outcome of interest (primary peanut sensitization at 8 years of age); this is probably because adult eczema is often non-atopic.
Genotyping was performed for FLG mutations common in Scandinavia using TaqMan allelic discrimination assays for R501X and R2447X and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for 2282del4. Children with a FLG mutation in any of these positions were classified as having a FLG loss-of-function mutation.
A reported history of infantile eczema was assessed by a validated eczema questionnaire with sensitivity of 92% and specificity of 100%. 22 Eczema was defined as dry skin, itchy rashes for 2 weeks or more and age-specific localization (face or arms/legs extension surfaces or arms/legs flexures or wrists/ankles flexures) and/or doctor's diagnosis of eczema after 3 months and up to 1 year of age.
Severity of eczema was assessed from questionnaires using three different measures: bags and stored at À20°C. Dust samples were sieved, and fine dust was weighed and extracted in proportional volumes of extraction solution as previously described. 24 Peanut protein in dust was determined using the Veratox polyclonal ELISA against whole peanut protein (Neogen Corporation, Lansing, MI, USA).
The lower limit of quantitation (LLQ) of the assay was defined as 100 ng/mL, and samples below this value were defined as 50 ng/ mL (LLQ/2). 25 Results were converted from ng/mL into lg peanut protein/g dust. Due to batch-to-batch variability of the Veratox ELISA, results were batch corrected prior to being entered into the final statistical analysis.
| Statistical analysis
Data were entered into an SPSS (SPSS 19.0; SPSS Inc, Chicago, IL, USA) and STATA spreadsheet (Timberlake Consultants Ltd London, UK) for the purpose of analysis. Peanut protein levels in dust (lg/g) underwent natural log transformation. Initial nested case-control analysis was performed with peanut sIgE-sensitized cases at 4 years of age-matched for sex and parental atopy with a 2:1 control (n = 274) to case (n = 137) matching. Children with primary peanut sensitization defined by Ara h 1, 2 or 3 ≥ 0.35kU/L at 8 years of age were matched against controls at age 8 years with the same sex and level of parental atopy with a 2:1 ratio of controls (n = 130) to cases (n = 65). Given that these controls were matched for the higher levels of parental atopy in the primary peanut-sensitized cases, these controls were deemed to be high-risk as the primary peanut-sensitized cases had higher levels of parental atopy than the population overall (46.7% vs 32.6%). Conditional logistic regression (incorporating matching) was performed for the case-control analysis using robust standard error for peanut sIgE sensitization at 4 years and primary peanut sensitization at age 8 years. 26, 27 Peanut levels in dust (lg/g) were compared between groups using the Mann-Whitney U test. Statistical significance was assessed at P < .05.
| RESULTS
Details of demographics and clinical characteristics included in this study are described in Table S1 . Differential relationship between EPE and primary peanut sensitization and non-clinically significant peanut sensitization is displayed in Figure 1 . Median peanut protein in dust was higher in peanut sIgE-sensitized children (3.39 lg/g, IQR 1.41-11.01, n = 137) than non-sensitized controls (2.28 lg/g, IQR 0.88-5.14, n = 274) (P < .01); and higher in primary peanut-sensitized children (4.64 lg/ g, IQR 1.58-12.77, n = 65) than in children that were not sensitized to Ara h 1, 2 or 3 (2.24 lg/g, IQR 0.88-4.74, n = 130) (P < .01).
On multivariate conditional logistic regression analysis, EPE was significantly associated with peanut-specific IgE and primary peanut sensitization with a 1.41-and 2.1-fold increase in odds of developing peanut sensitization per unit increase EPE, respectively (Table 2) .
Infantile eczema and egg sensitization were both significantly associated with sensitization to peanut protein component allergens Ara h 1, 2 and/or 3 ( Table 2) . FLG loss-of-function mutations increased the probability of developing peanut-specific IgE sensitization 3.78-fold and primary peanut sensitization 7.33-fold. Allergic rhinitis at age 8 years was associated with both the probability of developing peanut-specific IgE sensitization at age 4 years and primary peanut sensitization at age 8 years in the multivariate analysis. Allergic rhinitis was included to assess whether false-positive results for peanut sensitization were being found due to cross-reactivity with grass or tree pollens.
biological siblings, duration of exclusive and total breastfeeding and maternal age at baseline were not associated with peanut sensitization. There was no significant interaction between EPE and either infantile eczema, egg sensitization or FLG loss-of-function mutations on primary peanut sensitization (data not shown).
| Whole cohort analysis for peanut extract sIgE sensitization and primary peanut sensitization
In a second step, following positive findings obtained on case-control analysis, we assessed the relationship between early EPE and peanut sensitization in all children from the BAMSE cohort with available postnatal maternal bed dust and FLG genotyping (n = 1878). On both univariate (Table S2 ) and multivariate analyses (Table 3) , infantile eczema, egg sensitization at age 4 years, tree nut and soya allergy at age 8 years, FLG loss-of-function mutation and allergic rhinitis at age 8 years were associated with the probability of peanut sIgE sensitization at age 4 and 8 years. For primary peanut sensitization at age 8, significant associations were also seen on univariate (Table S2 ) and multivariate analyses (Table 3) for infantile eczema, egg sensitization, tree nut and soya allergy at age 8 years and allergic rhinitis at age 8 years. Although measures of eczema severity and several other food allergies at age 8 years were significantly associated with peanut sensitization on univariate analysis, these variables were no longer significantly associated in the multivariate analysis. EPE was not associated with peanut sIgE sensitization or primary peanut sensitization. There was no interaction between EPE and FLG mutations, infantile eczema, egg sensitization, allergic reaction to tree nut or soya by age 8 years, or parental atopy on peanut sensitization.
| Subgroup analysis of primary peanut sensitization against egg-sensitized non-peanut allergic individuals
On subgroup analysis, we compared primary peanut-sensitized children (n = 75) against children who were sensitized to egg (sIgE ≥ 0.35kU/L at age 4 years) but did not go on to have primary peanut sensitization at age 8 years (n = 59). EPE increased the probability of primary peanut sensitization on both univariate (OR=1.33 95% CI:1.01-1.74, P < .05, n = 134) ( We assessed the impact of EPE on peanut sensitization when using other high-risk groups of children who were not peanutsensitized at age 8 years (FLG mutations, infantile eczema, soya allergy and parental atopy), and there was no significant association.
| DISCUSSION
In the prospective birth cohort BAMSE, there was an exposureresponse relationship between EPE (quantified using peanut protein levels from maternal mattress dust postnatally) and primary peanut sensitization (Ara h 1, 2 or 3 ≥ 0.35kU/L) among high-risk children (in a nested cases analysis). When all children in the BAMSE cohort with available dust and FLG status were assessed, there was no association between EPE and peanut sensitization; however, on subgroup analysis, there was an exposure-response relationship between EPE and primary peanut sensitization when compared against high-risk egg-sensitized children. In the nested cases analysis, the exposure-response relationship was stronger between EPE and primary peanut sensitization (Ara h 1, 2 or 3 ≥ 0.35kU/L) than between EPE and non-clinically relevant peanut sensitization (peanut sIgE ≥0.35kU/L but negative results for Ara h 1, 2 or 3 < 0.35kU/L) ( Figure 1 ). This supports the concept that EPE increases the probability of developing clinically relevant peanut sensitization which is more likely to develop into peanut allergy rather than non-specific peanut sensitization.
In other cohorts, we have shown a synergistic effect between EPE and markers of an impaired skin barrier (infantile eczema and FLG loss-of-function mutations) on peanut sensitization and allergy. 11, 12 This follows the hypothesis that children with an inflamed disrupted skin barrier may become sensitized to food proteins in their environment via transcutaneous sensitization. 8 Although in BAMSE we did not find significant interactions between EPE and FLG mutations or infantile eczema on peanut sensitization, we did show on subgroup analysis that early EPE has more impact on the probability of developing peanut sensitization when compared against high-risk children (defined by parental atopy in the nested cases analysis and egg sensitization in the whole cohort analysis) than in children without these risk factors.
The BAMSE cohort is relatively non-atopic, being from the general population in Sweden, which may have contributed to lower strength of associations between EPE and peanut sensitization overall, and in other groups such as children with a history of eczema or filaggrin mutations. We did find an association between EPE and peanut sensitization when we compared primary peanut-sensitized children against children who were sensitized to egg but did not go on to have primary peanut sensitization. We postulated that children with egg sensitization who went onto develop peanut sensitization were probably exposed to a higher levels of EPE than those who did not go on to develop peanut sensitization as this reflected the findings by Fox et al who showed that household peanut consumption during the first year of life (as an indirect marker of EPE) was higher in peanut allergic cases than in egg-allergic controls. 13 Egg sensitization was highly associated with peanut sensitization in the BAMSE study, which has previously been shown in numerous other cohort studies; 11, 12, 28 it may be that egg sensitization shows a predisposition to mount allergic antibodies to other allergens as egg allergy is highly associated with the development of other food allergies, asthma and aeroallergen sensitization. 29, 30 Observational studies have shown that in children with severe, early-onset eczema, up to 50% are sensitized to egg; 31 thus, egg sensitization may be an additional marker of eczema severity and predisposition to transcutaneous sensitization. In fact, of children who were egg-sensitized at 4 years in BAMSE, there was a higher use of early topical steroids for eczema treatment (85.4% vs 69.5%) than in children without egg sensitization
We also considered other factors that may have influenced the differences found between the effects of EPE on peanut sensitization in BAMSE study vs other cohorts such as the level of peanut protein found in dust. 24 The level of peanut in dust was higher in a US study that measured peanut from the living room floor (median 39.1 lg/g IQR 0.4-1.33). 10 It would, however, be expected that T A B L E 2 Multivariate conditional logistic regression incorporating peanut-sensitized cases vs non-sensitized controls matched for sex and parental atopy. Peanut sIgE sensitization (≥0.35kU/L) at age 4 years and primary peanut sensitization (Ara h 1, 2 or 3 ≥ 0.35kU/L) at age 8 years. Non-Caucasians were excluded due to inclusion of FLG mutations as a covariate | 591 peanut levels would be higher in America due to higher levels of peanut consumption.
Infantile eczema was one of the most important risk factors for peanut sensitization in BAMSE; this association has been cited in numerous studies. 8, 31 Measures of eczema severity (extent of localization, topical steroid use and persistent eczema) were associated with peanut sensitization on univariate analysis but were no longer associated with multivariate analysis. Eczema severity has previous been shown to be an independent risk factor for food sensitization in the EAT (Enquiring About Tolerance) study. 32 The EAT study used the SCORAD eczema severity scoring system; however, this could not be performed in the BAMSE study as the evaluations at 1, 2, 4 and 8 years were based on parental questionnaires.
FLG loss-of-function mutations were less important than infantile eczema in predicting the development of peanut sensitization, and FLG mutations became more important if infantile eczema was not included in the regression model. Previous studies have found that children that carry a FLG mutation have an increased risk of peanut allergy even after adjusting for eczema. 33 In this study, eczema seemed to be the overriding factor for peanut sensitization; however, it should be noted that FLG mutations were quite low in BAMSE (7.14%) in comparison with other population-based cohorts. 26, 33, 34 Tree nut and/or soya allergy by age 8 was also associated with primary peanut sensitization at age 8 years; co-existent peanut and tree nut allergy have been shown in numerous studies, 35, 36 whereas co-existent soya and peanut allergy are reportedly low in other populations. 37 Strength of the present study includes the population-based design and relatively high number of study participants. Limitations of this study included the lack of diagnostic food challenges to determine peanut allergy as the BAMSE study was not originally designed to evaluate peanut allergic outcomes; however, primary peanut sensitization has been shown to be a much more accurate predictor of clinically confirmed peanut allergy than peanut-specific IgE. 38, 39 Certain potential confounders were not available such as parental peanut allergy or other parental food allergies, maternal peanut consumption during pregnancy and breastfeeding and infant peanut consumption. Therefore, we are unable to assess whether infant peanut consumption could have protected the children against environmental exposure to peanut as has been shown in previous studies; 13, 35 however, when BAMSE was recruiting participants in 1996, the number of infants eating peanut was very low. Caucasian ethnicity was based on place of parental birth rather than self-reported ethnicity; however, when the BAMSE study was recruiting participants 1994-1996, most parents born in Sweden or Northern Europe would have been of Caucasian descent. 40 Findings on case-control analysis could not be replicated on whole cohort analysis; therefore, these findings need to be confirmed in other population-based cohorts.
| CONCLUSION
In summary, although EPE did not increase the risk of peanut sensitization in children who did not already have atopic risk factors, the findings from the BAMSE cohort support the hypothesis that in specific high-risk groups, peanut levels in dust around the time of birth may pose a risk for later peanut sensitization. Further prospective studies are needed to confirm these findings in other populations.
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